Scarica l'app Stockscreener
18.80
4.79%
0.86
Dopo l'orario di chiusura:
18.69
-0.11
-0.59%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SRPT Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$17.94
Aprire:
$17.95
Volume 24 ore:
7.52M
Relative Volume:
0.69
Capitalizzazione di mercato:
$1.84B
Reddito:
$2.23B
Utile/perdita netta:
$-248.39M
Rapporto P/E:
-6.9888
EPS:
-2.69
Flusso di cassa netto:
$-697.55M
1 W Prestazione:
+12.24%
1M Prestazione:
+3.47%
6M Prestazione:
-82.88%
1 anno Prestazione:
-85.39%
Intervallo 1D:
$17.68
$18.85
Intervallo di 1 settimana:
$15.82
$19.26
Portata 52W:
$10.41
$144.22
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
Nome
Sarepta Therapeutics Inc
Settore
Industria
Telefono
617-274-4000
Indirizzo
215 FIRST STREET, CAMBRIDGE, MA
Confronta SRPT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
18.80 | 1.75B | 2.23B | -248.39M | -697.55M | -2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-29 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2025-07-29 | Iniziato | Bernstein | Mkt Perform |
| 2025-07-29 | Reiterato | H.C. Wainwright | Sell |
| 2025-07-29 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2025-07-29 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-07-28 | Downgrade | Barclays | Equal Weight → Underweight |
| 2025-07-25 | Downgrade | JP Morgan | Neutral → Underweight |
| 2025-07-24 | Iniziato | Citigroup | Sell |
| 2025-07-23 | Downgrade | BofA Securities | Neutral → Underperform |
| 2025-07-22 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-07-21 | Downgrade | Deutsche Bank | Buy → Hold |
| 2025-07-21 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-07-21 | Downgrade | Mizuho | Outperform → Neutral |
| 2025-07-21 | Downgrade | Needham | Hold → Underperform |
| 2025-07-21 | Downgrade | UBS | Buy → Neutral |
| 2025-07-18 | Downgrade | Needham | Buy → Hold |
| 2025-06-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-06-18 | Downgrade | TD Cowen | Buy → Hold |
| 2025-06-17 | Iniziato | Wolfe Research | Peer Perform |
| 2025-06-16 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2025-06-16 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-06-16 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-06-16 | Downgrade | H.C. Wainwright | Neutral → Sell |
| 2025-06-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-06-16 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2025-06-06 | Aggiornamento | Scotiabank | Sector Perform → Sector Outperform |
| 2025-05-08 | Downgrade | Evercore ISI | Outperform → In-line |
| 2025-04-11 | Iniziato | Wells Fargo | Overweight |
| 2025-04-02 | Aggiornamento | H.C. Wainwright | Sell → Neutral |
| 2025-03-31 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | Iniziato | Deutsche Bank | Hold |
| 2024-11-27 | Reiterato | Needham | Buy |
| 2024-11-25 | Iniziato | H.C. Wainwright | Sell |
| 2024-11-07 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2024-10-21 | Iniziato | Jefferies | Buy |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-07-29 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-06-26 | Downgrade | Citigroup | Buy → Neutral |
| 2024-05-31 | Iniziato | Piper Sandler | Overweight |
| 2024-05-28 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-05-14 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2024-01-31 | Iniziato | BMO Capital Markets | Outperform |
| 2023-12-13 | Ripresa | Citigroup | Buy |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-11-21 | Iniziato | Wedbush | Outperform |
| 2023-10-31 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-31 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-06-23 | Downgrade | Evercore ISI | Outperform → In-line |
| 2023-04-26 | Iniziato | SMBC Nikko | Outperform |
| 2023-04-04 | Iniziato | Citigroup | Buy |
| 2023-03-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-12-22 | Reiterato | BTIG Research | Buy |
| 2022-12-16 | Aggiornamento | UBS | Neutral → Buy |
| 2022-04-04 | Ripresa | Cantor Fitzgerald | Overweight |
| 2022-01-05 | Reiterato | Needham | Buy |
| 2021-12-09 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-11-05 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-09-15 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-08-05 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-04-26 | Ripresa | Credit Suisse | Neutral |
| 2021-01-12 | Downgrade | Citigroup | Buy → Neutral |
| 2021-01-11 | Downgrade | UBS | Buy → Neutral |
| 2021-01-08 | Downgrade | JP Morgan | Overweight → Underweight |
| 2021-01-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-01-08 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | Iniziato | Berenberg | Hold |
| 2020-10-28 | Iniziato | UBS | Buy |
| 2020-08-25 | Iniziato | Raymond James | Outperform |
| 2020-08-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2020-03-31 | Iniziato | Mizuho | Buy |
| 2019-11-01 | Iniziato | Guggenheim | Buy |
| 2019-08-21 | Reiterato | Needham | Buy |
| 2019-07-09 | Reiterato | Morgan Stanley | Overweight |
| 2019-07-01 | Reiterato | RBC Capital Mkts | Outperform |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-03-11 | Reiterato | Credit Suisse | Outperform |
| 2018-10-12 | Iniziato | Bernstein | Outperform |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-09-26 | Reiterato | RBC Capital Mkts | Outperform |
| 2018-09-14 | Ripresa | BofA/Merrill | Buy |
| 2018-09-06 | Iniziato | Credit Suisse | Outperform |
| 2018-08-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2018-06-21 | Reiterato | Robert W. Baird | Outperform |
| 2018-06-20 | Reiterato | Needham | Buy |
| 2018-06-19 | Reiterato | H.C. Wainwright | Buy |
Mostra tutto
Sarepta Therapeutics Inc Borsa (SRPT) Ultime notizie
2025-08-12 | Lost Money on Sarepta Therapeutics, Inc. (SRPT)? Contact Levi & Korsinsky Before August 25, 2025 to Join Class Action | NDAQ:SRPT | Press Release - Stockhouse
Brutal 2025 for Sarepta—Analysts Still Call for 179% Upside - MarketBeat
Sarepta details Elevidys’ liver toxicity data and plans for safety study - Endpoints News
Caught In Sarepta ‘Downdraft,’ Arrowhead Becomes RNAi Knight in Shining Armor - BioSpace
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP - GlobeNewswire
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics - FinancialContent
Levi & Korsinsky Urges Sarepta Therapeutics, Inc. (SRPT) Shareholders to Act Before Lead Plaintiff Deadline August 25, 2025 - ACCESS Newswire
SAREPTA (SRPT) LAWSUIT ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
Vinay Prasad returns to role as top vaccine regulator at FDA days after leaving US agency - Reuters
August 25, 2025 Deadline Approaching: Join Class Action Against Sarepta Therapeutics, Inc. (SRPT)Contact Levi & Korsinsky - Newsfile
SRPT COURT REMINDER: Sarepta Therapeutics, Inc. was Sued for Fraud -- Investors are Notified to Contact BFA Law by August 25 Deadline - ACCESS Newswire
Sarepta Therapeutics, Inc. Securities Fraud Class Action - GlobeNewswire
Sarepta Therapeutics (SRPT) Declines Again On EMA - GlobeNewswire
Sarepta stock rises as Jefferies reiterates Buy rating after Elevidys shipments resume - Investing.com Canada
Sarepta stock rating upgraded to Buy by Freedom Broker on ELEVIDYS supply resumption - Investing.com Canada
A mild market reaction for companies on Prasad’s return - BioWorld MedTech
Vinay Prasad's Comeback To FDA Sparks Debate Over Regulatory Direction - Benzinga
SRPT LAWSUIT ALERT: The Gross Law Firm Notifies Sarepta Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - Morningstar
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
Unexpected Shifts in the Gene Transfer Technologies Market - openPR.com
SRPT COURT NOTICE: Sarepta Therapeutics Investors may have - GlobeNewswire
Vinay Prasad’s Return to FDA Sends Biotech Shares Tumbling - Bloomberg.com
Vor Bio lures Sarepta exec to be its CCO - The Pharma Letter
SRPT Lawsuit Alert! Class Action Lawsuit Against Sarepta Therapeutics - TipRanks
Biotech sector slips amid reported return of ousted FDA official - MSN
Biotech sector slips amid reported return of ousted FDA official (SRPT:NASDAQ) - Seeking Alpha
Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Expected to Rise, The Goldman Sachs Group Analyst Says - Defense World
Sarepta’s Woes Put the Stalwart AAV Under a Harsh Light - BioSpace
Levi & Korsinsky Notifies Sarepta Therapeutics, Inc. (SRPT) InvestorsLead Plaintiff Deadline on August 25, 2025 - ACCESS Newswire
Shareholders of Sarepta Therapeutics, Inc. (SRPT): Protect Your Rights Before August 25, 2025Contact Levi & Korsinsky - ACCESS Newswire
SRPT DEADLINE ALERT: ROSEN, NATIONAL TRIAL COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – SRPT - GlobeNewswire Inc.
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics - TradingView
Sarepta Therapeutics (NASDAQ:SRPT) Price Target Raised to $19.00 at The Goldman Sachs Group - Defense World
Sarepta Therapeutics (NASDAQ:SRPT) Price Target Raised to $19.00 - Defense World
Levi & Korsinsky Notifies Sarepta Therapeutics, Inc. (SRPT) Shareholders of Class Action Lawsuit and August 25, 2025 Deadline - ACCESS Newswire
2025-08-09 | Levi & Korsinsky Notifies Sarepta Therapeutics, Inc. (SRPT) Shareholders of Class Action Lawsuit and August 25, 2025 Deadline | NDAQ:SRPT | Press Release - Stockhouse
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesSRPT | FinancialContent - FinancialContent
SRPT INVESTOR NOTICE: Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - PR Newswire
Shareholders that lost money on Sarepta Therapeutics, - GlobeNewswire
SRPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
SRPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Morningstar
SRPT ALERT: BFA Law Urges Sarepta Therapeutics, Inc. Investors with Losses to Contact the Firm before the Imminent August 25 Court Deadline - Newsfile
SRPT Deadline: SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit - Barchart.com
Precision Trading with Sarepta Therapeutics Inc. (SRPT) Risk Zones - news.stocktradersdaily.com
Securities Lawsuit Alert: Sarepta Therapeutics, Inc. (SRPT) InvestorsContact Levi & Korsinsky Before August 25, 2025 - Barchart.com
Duchenne Muscular Dystrophy Market Set to Grow Substantially Through 2034, DelveInsight Projects | Sarepta Therapeutics, Santhera Pharma, ReveraGen Biopharma, Pfizer, FibroGen, Capricor Therapeutics - Barchart.com
Elevidys sales weaken; Neumora gets into obesity - BioPharma Dive
As gene therapies falter on the market, this biopharma is aiming to defy the odds - PharmaVoice
Vor Bio hires former Sarepta exec to lead commercial strategy; Mallinckrodt poaches CFO from Incyte - Endpoints News
How Sarepta Therapeutics Inc. (SRPT) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Sarepta soars as revenue beats estimates on Elevidys milestone - The Boston Globe
Sarepta Therapeutics Inc Azioni (SRPT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.91%
3.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):